In Q1, we generated cash from operations of $4,000,000 compared to $5,800,000 last year. Cash and cash equivalents were at $21,200,000 at March 31, up from $20,700,000 at year end. With solid fundamentals in place, increasingly diversified revenue, sustained adjusted EBITDA and reliable cash from operations, we have continued to deleverage the business From a total of $185,000,000 of debt at the company's inception down to $95,200,000 at the end of Q1. In addition to the positive cash flow from operations in the quarter, more than $20,000,000 in cash and strong prospects for improved cash flows From Vascepa and Clozril, there's also an undrawn revolver facility of $26,500,000 and HLS can request incremental loans Up to a maximum of $70,000,000 to support growth opportunities. As Craig mentioned, after careful deliberation, The Board has canceled our dividend policy as we believe that allocating more funds to the NCIB, which particularly when our stock is trading at these levels, is a more effective way to return capital to shareholders.